China Seen As The Prize In The Race For HCV Dominance
This article was originally published in PharmAsia News
As Gilead and AbbVie battle for new hepatitis C treatment options, Roche is hoping a trailing product can find a home in China, where genotype 1b HCV is most prevalent.
You may also be interested in...
Company also updates Phase II ELECTRON data from November, showing all nine patients in a null-responder cohort achieved sustained virological response after four weeks of therapy with combo.
For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.
China’s Simcere Receives Buyout Offer From Its Chairman, But Could Delisting Be A Negative Overseas?
Simcere would join Chinese firms 3SBio and ShangPharma in pulling out of the U.S. stock market.